华熙生物(688363) - 2020 Q3 - 季度财报

Financial Performance - Operating income for the first nine months rose by 23.96% to CNY 1,596,437,349.97 year-on-year[5] - Net profit attributable to shareholders increased by 5.12% to CNY 437,565,648.99 compared to the same period last year[5] - Net cash flow from operating activities surged by 84.29% to CNY 381,319,230.93 year-to-date[5] - Total operating revenue for Q3 2020 reached ¥649,160,397.14, a 35.7% increase from ¥478,549,257.07 in Q3 2019[26] - Net profit for Q3 2020 was ¥170,421,327.08, up 12.5% from ¥150,920,125.91 in Q3 2019[27] - Total comprehensive income for the first nine months of 2020 was ¥456.17 million, compared to ¥405.75 million in the same period of 2019, marking a 12.4% increase[32] Assets and Liabilities - Total assets increased by 6.75% to CNY 5,307,334,724.12 compared to the end of the previous year[5] - The company’s total assets as of September 30, 2020, amounted to ¥3,654,311,560.54, a slight decrease from ¥3,770,683,144.66 as of December 31, 2019[21] - Total liabilities increased to ¥492,275,717.01 from ¥422,105,730.03, representing a growth of about 16.6%[23] - Current liabilities decreased to ¥345,267,972.04 from ¥365,695,722.26, a reduction of approximately 5.88%[22] - Non-current assets totaled ¥961,202,769.76, including long-term equity investments of ¥695,182,456.85 and fixed assets of ¥109,852,500.96[43] Cash Flow - Cash flow from operating activities for the first nine months of 2020 was ¥1.88 billion, compared to ¥1.33 billion in the same period of 2019, indicating a growth of 41.4%[33] - The net cash flow from operating activities for the first three quarters of 2020 was ¥307,182,223.59, compared to ¥91,441,801.13 in the same period of 2019, representing a significant increase[36] - Total cash inflow from operating activities reached ¥1,102,299,211.09, up from ¥788,479,061.11 year-over-year, indicating a growth of approximately 40%[35] - The net cash flow from investment activities was -¥699,144,062.39, worsening from -¥238,706,164.17 in the same period last year[36] Research and Development - R&D expenditure as a percentage of operating income increased by 1.68 percentage points to 5.98%[7] - Research and development expenses rose by 72.65% to ¥95,517,491.18, driven by an increase in R&D personnel and project development costs[15] - Research and development expenses for Q3 2020 amounted to ¥35,808,951.34, a significant increase from ¥17,869,651.66 in Q3 2019[26] Shareholder Information - The total number of shareholders at the end of the reporting period was 12,818[10] - The largest shareholder, Huaxi Xinyu Investment Co., Ltd., holds 59.06% of the shares[10] - Shareholders' equity rose to ¥4,815,059,007.11, compared to ¥4,549,554,137.63, an increase of approximately 5.85%[23] Other Income and Expenses - Government subsidies recognized in the current period amounted to CNY 24,183,107.10[8] - The company reported a significant increase of 362.68% in other income to ¥51,168,877.60, primarily due to increased government subsidies received during the period[15] - The company’s financial expenses included interest payments of ¥7.93 million in Q3 2020, compared to a negative interest expense of -¥11.04 million in Q3 2019[30]